Head-to-head evidence
225Ac-FPI-2068 vs EMB-01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline
225Ac-FPI-2068
Developed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06147037 (registry estimate)
EMB-01
Marketed by Shanghai EpimAb Biotherapeutics
NCT03797391 · Phase 1/2 · status unknown
This was an open-label, non-randomized, single-arm dose-escalation and expansion study of EMB-01 in patients with advanced solid tumors, with no control group, so it cannot reliably show the drug's effect versus no treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 225Ac-FPI-2068's landscape · EMB-01's landscape